Thrombocytopenia-Pipeline Review, H1 2015

Thrombocytopenia-Pipeline Review, H1 2015

  • Products Id :- GMDHC6698IDB
  • |
  • Pages: 188
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Thrombocytopenia-Pipeline Review, H1 2015


Global Markets Direct's, 'Thrombocytopenia-Pipeline Review, H1 2015', provides an overview of the Thrombocytopenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Thrombocytopenia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Thrombocytopenia Overview 8

Therapeutics Development 9

Pipeline Products for Thrombocytopenia-Overview 9

Pipeline Products for Thrombocytopenia-Comparative Analysis 10

Thrombocytopenia-Therapeutics under Development by Companies 11

Thrombocytopenia-Therapeutics under Investigation by Universities/Institutes 15

Thrombocytopenia-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Thrombocytopenia-Products under Development by Companies 19

Thrombocytopenia-Products under Investigation by Universities/Institutes 22

Thrombocytopenia-Companies Involved in Therapeutics Development 23

Ablynx NV 23

Anthera Pharmaceuticals Inc. 24

Archemix Corp. 25

Arcturus Therapeutics, Inc 26

aTyr Pharma, Inc. 27

Bayer AG 28

BioLineRx, Ltd. 29

Boehringer Ingelheim GmbH 30

Bolder Biotechnology, Inc. 31

Bristol-Myers Squibb Company 32

Cellerant Therapeutics, Inc. 33

Eisai Co., Ltd. 34

GlaxoSmithKline Plc 35

Glenmark Pharmaceuticals Ltd. 36

HanAll Biopharma Co., Ltd. 37

Immunomedics, Inc. 38

InvivoGen Therapeutics 39

Jiangsu Hengrui Medicine Co., Ltd. 40

Kaketsuken K.K. 41

Merck & Co., Inc. 42

Momenta Pharmaceuticals, Inc. 43

Myelo Therapeutics GmbH 44

Neumedicines Inc. 45

Novartis AG 46

Octapharma AG 47

Omeros Corporation 48

Pfizer Inc. 49

PhytoHealth Corporation 50

Portola Pharmaceuticals, Inc. 51

Prophylix Pharma AS 52

Protalex, Inc. 53

Rigel Pharmaceuticals, Inc. 54

Shionogi & Co., Ltd. 55

STATegics, Inc. 56

ViroMed Co., Ltd. 57

Thrombocytopenia-Therapeutics Assessment 58

Assessment by Monotherapy Products 58

Assessment by Target 59

Assessment by Mechanism of Action 61

Assessment by Route of Administration 63

Assessment by Molecule Type 65

Drug Profiles 67

Antibody for Autoimmune Disorders and Inflammation-Drug Profile 67

ARC-15105-Drug Profile 68

avatrombopag-Drug Profile 69

BAX-930-Drug Profile 71

BBT-030-Drug Profile 73

BBT-045-Drug Profile 74

BI-655064-Drug Profile 75

BL-8040-Drug Profile 76

blisibimod-Drug Profile 78

BMS-986004-Drug Profile 81

caplacizumab-Drug Profile 82

CLT-009-Drug Profile 84

eltrombopag olamine-Drug Profile 85

fostamatinib disodium-Drug Profile 88

GBR-600-Drug Profile 91

Gene Therapy for Chemotherapy-Induced Thrombocytopenia-Drug Profile 92

GL-2045-Drug Profile 93

GSK-2285921-Drug Profile 94

Hetrombopag Olamine-Drug Profile 96

HL-161-Drug Profile 97

LUNAR-TPO-Drug Profile 98

lusutrombopag-Drug Profile 99

MK-8723-Drug Profile 100

Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders-Drug Profile 101

Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders-Drug Profile 102

Myelo-001-Drug Profile 104

NMIL-121-Drug Profile 105

Oligonucleotides to Activate miRNA-150 for Thrombocytopenia-Drug Profile 107

OMS-721-Drug Profile 108

PEG-VM501-Drug Profile 110

PHN-013-Drug Profile 111

plasma (human)-Drug Profile 112

PRT-060318-Drug Profile 113

PRTX-100-Drug Profile 114

rivaroxaban-Drug Profile 116

SM-101-Drug Profile 121

STST-4-Drug Profile 124

Tmax-Drug Profile 125

Tromplate-Drug Profile 126

TXA-302-Drug Profile 127

veltuzumab-Drug Profile 129

Thrombocytopenia-Recent Pipeline Updates 132

Thrombocytopenia-Dormant Projects 173

Thrombocytopenia-Discontinued Products 176

Thrombocytopenia-Product Development Milestones 177

Featured News & Press Releases 177

Appendix 184

Methodology 184

Coverage 184

Secondary Research 184

Primary Research 184

Expert Panel Validation 184

Contact Us 184

Disclaimer 185

List of Tables

Number of Products under Development for Thrombocytopenia, H1 2015 12

Number of Products under Development for Thrombocytopenia-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Products under Development by Companies, H1 2015 22

Products under Development by Companies, H1 2015 (Contd..1) 23

Products under Development by Companies, H1 2015 (Contd..2) 24

Products under Investigation by Universities/Institutes, H1 2015 25

Thrombocytopenia-Pipeline by Ablynx NV, H1 2015 26

Thrombocytopenia-Pipeline by Anthera Pharmaceuticals Inc., H1 2015 27

Thrombocytopenia-Pipeline by Archemix Corp., H1 2015 28

Thrombocytopenia-Pipeline by Arcturus Therapeutics, Inc, H1 2015 29

Thrombocytopenia-Pipeline by aTyr Pharma, Inc., H1 2015 30

Thrombocytopenia-Pipeline by Bayer AG, H1 2015 31

Thrombocytopenia-Pipeline by BioLineRx, Ltd., H1 2015 32

Thrombocytopenia-Pipeline by Boehringer Ingelheim GmbH, H1 2015 33

Thrombocytopenia-Pipeline by Bolder Biotechnology, Inc., H1 2015 34

Thrombocytopenia-Pipeline by Bristol-Myers Squibb Company, H1 2015 35

Thrombocytopenia-Pipeline by Cellerant Therapeutics, Inc., H1 2015 36

Thrombocytopenia-Pipeline by Eisai Co., Ltd., H1 2015 37

Thrombocytopenia-Pipeline by GlaxoSmithKline Plc, H1 2015 38

Thrombocytopenia-Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 39

Thrombocytopenia-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 40

Thrombocytopenia-Pipeline by Immunomedics, Inc., H1 2015 41

Thrombocytopenia-Pipeline by InvivoGen Therapeutics, H1 2015 42

Thrombocytopenia-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 43

Thrombocytopenia-Pipeline by Kaketsuken K.K., H1 2015 44

Thrombocytopenia-Pipeline by Merck & Co., Inc., H1 2015 45

Thrombocytopenia-Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 46

Thrombocytopenia-Pipeline by Myelo Therapeutics GmbH, H1 2015 47

Thrombocytopenia-Pipeline by Neumedicines Inc., H1 2015 48

Thrombocytopenia-Pipeline by Novartis AG, H1 2015 49

Thrombocytopenia-Pipeline by Octapharma AG, H1 2015 50

Thrombocytopenia-Pipeline by Omeros Corporation, H1 2015 51

Thrombocytopenia-Pipeline by Pfizer Inc., H1 2015 52

Thrombocytopenia-Pipeline by PhytoHealth Corporation, H1 2015 53

Thrombocytopenia-Pipeline by Portola Pharmaceuticals, Inc., H1 2015 54

Thrombocytopenia-Pipeline by Prophylix Pharma AS, H1 2015 55

Thrombocytopenia-Pipeline by Protalex, Inc., H1 2015 56

Thrombocytopenia-Pipeline by Rigel Pharmaceuticals, Inc., H1 2015 57

Thrombocytopenia-Pipeline by Shionogi & Co., Ltd., H1 2015 58

Thrombocytopenia-Pipeline by STATegics, Inc., H1 2015 59

Thrombocytopenia-Pipeline by ViroMed Co., Ltd., H1 2015 60

Assessment by Monotherapy Products, H1 2015 61

Number of Products by Stage and Target, H1 2015 63

Number of Products by Stage and Mechanism of Action, H1 2015 65

Number of Products by Stage and Route of Administration, H1 2015 67

Number of Products by Stage and Molecule Type, H1 2015 69

Thrombocytopenia Therapeutics-Recent Pipeline Updates, H1 2015 135

Thrombocytopenia-Dormant Projects, H1 2015 176

Thrombocytopenia-Dormant Projects (Contd..1), H1 2015 177

Thrombocytopenia-Dormant Projects (Contd..2), H1 2015 178

Thrombocytopenia-Discontinued Products, H1 2015 179

List of Figures

Number of Products under Development for Thrombocytopenia, H1 2015 12

Number of Products under Development for Thrombocytopenia-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Products, H1 2015 21

Assessment by Monotherapy Products, H1 2015 61

Number of Products by Top 10 Targets, H1 2015 62

Number of Products by Stage and Top 10 Targets, H1 2015 62

Number of Products by Top 10 Mechanism of Actions, H1 2015 64

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 64

Number of Products by Top 10 Routes of Administration, H1 2015 66

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 66

Number of Products by Top 10 Molecule Types, H1 2015 68

Number of Products by Stage and Top 10 Molecule Types, H1 2015 68

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Ablynx NV

Anthera Pharmaceuticals Inc.

Archemix Corp.

Arcturus Therapeutics, Inc

aTyr Pharma, Inc.

Bayer AG

BioLineRx, Ltd.

Boehringer Ingelheim GmbH

Bolder Biotechnology, Inc.

Bristol-Myers Squibb Company

Cellerant Therapeutics, Inc.

Eisai Co., Ltd.

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd.

HanAll Biopharma Co., Ltd.

Immunomedics, Inc.

InvivoGen Therapeutics

Jiangsu Hengrui Medicine Co., Ltd.

Kaketsuken K.K.

Merck & Co., Inc.

Momenta Pharmaceuticals, Inc.

Myelo Therapeutics GmbH

Neumedicines Inc.

Novartis AG

Octapharma AG

Omeros Corporation

Pfizer Inc.

PhytoHealth Corporation

Portola Pharmaceuticals, Inc.

Prophylix Pharma AS

Protalex, Inc.

Rigel Pharmaceuticals, Inc.

Shionogi & Co., Ltd.

STATegics, Inc.

ViroMed Co., Ltd.

Thrombocytopenia Therapeutic Products under Development, Key Players in Thrombocytopenia Therapeutics, Thrombocytopenia Pipeline Overview, Thrombocytopenia Pipeline, Thrombocytopenia Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]